nach oben

Erschienen in:

01.02.2023 | Clinical study

Biological and target synthetic DMARDs have differing infection risks

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Biological disease-modifying antirheumatic drugs (bDMARDs) and target synthetic DMARDs (tsDMARDs) have generally similar safety profiles but some differences in infection risks, according to findings of a nationwide Swedish study published in Annals of Rheumatic Diseases . …

Frisell T, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Annals of the Rheumatic Diseases : 14 Feb 2023. Available from: URL: http://doi.org/10.1136/ard-2022-223762

Titel: Biological and target synthetic DMARDs have differing infection risks
Publikationsdatum: 01.02.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-34088-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Biological and target synthetic DMARDs have differing infection risks

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Antiepileptic-drugs/prednisolone

Cisplatin/gemcitabine

Perindopril/torasemide

Recombinant-factor-viia/tranexamic-acid

Antineoplastics/venetoclax

Prednisone